HCI Group, Inc.
HCI · NYSE
Analyst ratings
strong_buy · 2 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| November 10, 2025 | Citizens | Maintains | Market Outperform | $255.00 |
| November 7, 2025 | Truist Securities | Maintains | Buy | $235.00 |
Florida insurance cycle sustainability and growth outlook
HCI enters the next Florida insurance cycle from a position of strength, with historically strong profitability, a favorable tort environment, and excess capital. Structural differences from prior soft-market periods mean investors are underweighting the durability of the current environment, making the stock's recent derating an overreaction.
Citizens' takeout opportunities are diminishing, and growth will likely slow from recent hard-market levels. The market may be overestimating the durability of current underwriting momentum, and low-multiple insurers can remain value traps when earnings are highly weather- and reserve-dependent.
Proprietary technology (Exzeo) as a sustainable competitive advantage
Continued investment in HCI's proprietary Exzeo technology platform enables more efficient policy selection, lower loss ratios, and higher retention rates. This technology edge is expected to drive net margin expansion and sustainable earnings growth, supporting a fair value estimate of $245 per share.
Despite the technology narrative, future earnings are forecast to shrink and margins are projected to compress from today's levels. The higher valuation thesis depends on a richer earnings multiple several years out, which is difficult to justify given HCI's heavy Florida concentration and rising reinsurance costs.
Valuation attractiveness versus earnings risk and estimate drift
HCI trades at a significant discount to analyst price targets and estimated intrinsic value, with a forward P/E of 7.64 versus the industry's 12.52. Strong recent earnings — $5.45 EPS beating the $5.26 consensus — and a 30.88% return on equity suggest the stock is meaningfully undervalued.
The Zacks consensus EPS estimate has drifted down and the stock carries a Zacks Rank #4 (Sell). A low P/E is only attractive if loss ratios, reserve development, and reinsurance costs remain stable — one adverse turn can erase multiple years of EPS growth in a single quarter, making the discount a potential value trap.